BCIC takes pride in the incredible fundraising achievements of past winners from the Biomedical Pitch Competition. Over the past three years, our winners have secured more than $100 million in funding, demonstrating the competition’s impact in connecting top entrepreneurs with leading VCs, MNCs, and Angel investors.
BCIC remains committed to providing the best platform for innovative startups to gain exposure and accelerate growth. Entrepreneurs are invited to join The 2025 Biomedical Pitch Competition by Mar 31st, 2025 and seize this opportunity!
A Track Record of Impact
2024 Pitch Competition Highlights
- Rapafusyn raised $28 million successfully (https://bcicglobal.org/rapafusyn_raised_28mil/)
- Agilis successfully secured $10 million from a Singapore family office (https://bcicglobal.org/agilis_raised_10mill/)
- GV20 secured funding, led by a family office with investment over $10 million (https://bcicglobal.org/dv20_secured_funding/)
- At least one more startup got a term sheet already
- At least two startups landed in Asia
2023 Pitch Competition Highlights
- Myrobalan raised $24 million successfully in the US within 5 months after participating in the pitch competition. (https://bcicglobal.org/myrobalan-therapeutics-secures-funding-of-24-million/)
- Two startups raised $1mil and $2mil separately.
- At least one startup landed in Asia
2022 Pitch Competition Highlights
- Amytrx has raised $18 million
- ARIZ Precision Medicine has raised $3 million
- Biostage has raised $5 million.
- Two startups landed in Asia
2025 Biomedical Pitch Competition Registration
You are invited to the 2025 Biomedical Pitch Competition, connecting biomedical start-ups with investors and other business accelerator resources. Please submit your applications by March 31st, 2025. All biomedical startups from concept to pre-IPO are welcome to participate.
Benefits of Firms Participating in Pitch Competition?
–Potential direct equity investment from 200+ Angel/VC funds/MNCs
-Many top-tier VCs & MNCs serve as final judges
–Fundraising, License Out or NewCo opportunities for your technology
-Partnership opportunities from venture capitalists, serial entrepreneurs, corporate executives, and attorneys
-Media exposure through partners’ networks. (20k+ views)
Timeline:
The deadline for registration is March 31st, 2025
Preliminary Pitches: April, 2025
Semi Final Pitches：May, 2025
Final Contest: June 14th, 2025
Please register by scanning the QR Code or using the link below
http://bcicglobal.mikecrm.com/w9wB3Ht
Startups Requirements:
- Comply with the relevant laws, regulations, and policies of the United States and residing countries, and do not infringe on the intellectual property rights and other legal rights of others. Individuals, teams, and companies participating in the competition shall be responsible for the authenticity and accuracy of the registration information.
- The ideas or products submitted are innovative and original with certain social and market value.
- Startups must be in the biomedical industry or sub-industries.
- Specify the individual, company, or team in the application.
- No restriction on participants’ nationality. Any entities looking for Chinese-funded or US-funded are welcome to participate.
Final Judges will be from
- Hong Kong Science and Technology Parks Corporation (HKSTP)
- F Prime
- SOSV
- Roche Accelerator
- AbbVie Ventures (To be Confirmed)
- Amgen Ventures (To be Confirmed)
- Kendall Capital Partners (KCP)
- PagodaTree Partners
- etc
Co-organizers:
| Name | Description |
| Boston Capital Investment Club (BCIC) | Boston Capital Investment Club is a non-profit organization founded in 2010 with nearly 10,000 members in Finance, Venture Capital, and various technology industries. It serves as Boston centered platform for exchanging ideas, knowledge, and information in finance and related areas between USA and China. Since 2022, the organization has hosted annual biomedical pitch competitions, empowering startups to secure over $100 million in collective funding. https://bcicglobal.org/ |
| Hong Kong Science and Technology Parks Corporation (HKSTP) | With a 20-year history of transforming lives through innovation, technology and entrepreneurship, Hong Kong Science and Technology Parks Corporation (HKSTP) has been propelling success for the most creative minds and innovators around the globe, accelerating ambitions and delivering positive impact from Hong Kong to the Greater Bay Area and the world. As an advocate for the innovative spirit, we strive to cultivate a diverse talent pool, connect research to innofacturing through “new industrialisation”, and create a well-established I&T ecosystem that bridges innovators with high-potential partners and investors for ideas to grow and thrive. https://www.hkstp.org/ |
Partners List for helping to promote this event:
| Harvard Life LabHarvard Innovation LabsHarvard Wyss InstituteHarvard Medical School CSSAOhio State University College of Pharmacy Innovation Center Pittsburg University Healthcare IncubatorStanford University Healthcare Innovation Lab – Stanford PipelineNest.BioNetherlands Innovation Center (NIC)Frees Fund JJLake Asia Future Innovation Challenger Boston ChapterDane CapitalAquilliusSimcere TherapeuticalBlue Ocean Capital GroupChinese Entrepreneurs Organization at Duke (DukeCEO) | Yale Venture Club The Hopkins Club for Innovation and EntrepreneurshipAsia America Innovation Alliance (AAIA)GeneOnlineLife-Science Entrepreneurship and Plus (LEAP)Huazhong University of Science and Technology (HUST) Boston Alumni Association Tongji Medical College of HUST Boston Chapter YuanBio Venture Capital AAEAPagodaTree PartnersAbbVie VenturesF PrimeAmgen VenturesTOP Innovation Districts LabThe Chinese Antibody Society (CAS)Penn Quakers Venture Club | VIVAMedicilonATLATLXingu ChuangfuAlliance of Venture and Entrepreneurs Organization for Chinese Students Alumni at Harvard S-Tron Danen CapitalAssociation d’Incubateur Franco-Chinois (AIFC) Brandeis ImpactChinese Entrepreneurs Organization CuBio Innovation CenterHiMedHuaSu Future Eisai Innovation IncRegent AdvisorsEnterprise Singapore Massachusetts Biomedical Initiatives (MBI)Greenberg TraurigBaker MckenzieK2VCBio2 Innovation Center |
Contact Us
Please send any questions via email: info@bcicglobal.org
Website: www.bcicglobal.org
WeChat Platform: bcicglobal
GV20 Therapeutics: AI-driven Next-generation Cancer Biotherapeutics
GV20 Therapeutics is a clinical-stage biotechnology company pioneering the integration of artificial intelligence (AI), genomics, and cancer immunology to develop novel cancer biotherapeutics. Their proprietary platform harnesses AI to decode patients’ natural B cell responses from large cohorts of tumor profiles, enabling simultaneous discovery of novel targets and therapeutic antibodies. GV20’s discovery pipeline spans best-in-class and first-in-class monoclonal and bispecific antibodies, as well as antibody-drug conjugates (ADCs), reflecting their comprehensive approach to innovative cancer therapy.
The company’s lead program, GV20-0251, exemplifies their groundbreaking approach: an AI-designed, first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting the novel immune checkpoint IGSF8. Preclinical studies demonstrated that GV20-0251 inhibits tumor growth through enhancing natural killer (NK) cell cytotoxicity, boosting dendritic cell-mediated antigen cross-priming, and activating T cells, both as a monotherapy and in combination with anti-PD1. In a U.S. multi-center Phase 1 clinical trial (NCT05669430) with advanced solid tumor patients, GV20-0251 has shown favorable safety profiles and promising monotherapy efficacy, particularly in cutaneous melanoma patients with primary resistance to anti-PD1. Setting a new standard in drug development speed, GV20-0251 progressed from target discovery to IND in just three years. As the first AI-designed antibody drug against an AI-predicted target to reach the clinic, it represents a paradigm shift in cancer drug development and demonstrates AI’s potential to unlock critical insights from patient profiles, potentially transforming outcomes for cancer patients.
Rapafusyn Pharmaceuticals
Rapafusyn Pharmaceuticals is an innovative near-clinical stage biotech company pioneering RapaGlues™, a unique modality to address previously undruggable targets. RapaGlues™ are non-degrading molecular glues which bind FKBP, an abundant intracellular protein, bringing FKBP in proximity with a target of interest allowing formation of new protein-protein interactions to block a target’s function.
There are several marketed natural products that have similar FKBP binding mechanisms validating the approach. Rapafusyn has developed platform technology to extend nature’s mechanism to a broad range of high-value targets including protein-protein interactions, intracellular domains of transmembrane proteins (enabling biologic substitution), SLCs and ion channels.
Leveraging our industry leading libraries of RapaGlues™, we have developed an exciting pipeline of assets addressing areas of high unmet medical need. We have identified our first development candidate for the prevention of Acute Kidney Injury, a common severe complication of cardiac surgery with no approved treatments. In addition, we also have several first-in-class or highly differentiated best-in-class programs in development for high-value immunology, oncology and neurological targets.
Agilis Robotic
Founded in 2021, the Hong Kong-based Agilis Robotics specializes in developing innovative surgical robots designed to operate through natural orifices such as the urethra, mouth, or anus, eliminating the need for external incisions to treat early-stage tumours.
The company’s robotic system has reached the critical stages of regulatory applications to the FDA and NMPA. If approved, it is poised to become the first commercially available robotic system for transurethral bladder tumour resection.
With its unique technological advantages and significant market potential, the company has secured more than US$17 million in funding, positioning itself as a leader in natural orifice surgical robotics.
In 2024, Agilis Robotics has announced the successful completion of the world’s first robot-assisted en-bloc resection of a bladder tumour (ERBT) using its self-developed, fully flexible endoscopic surgical robotic system. The successful demonstration of robot-assisted ERBT not only provides a breakthrough treatment option for bladder cancer but also opens the door to broader applications of minimally invasive robotic surgery through natural orifices, including procedures for the colon and upper gastrointestinal tract.
Agilis Robotics is committed to advancing medical technology, driving innovation, and delivering impactful solutions that benefit patients worldwide.
Myrobalan Therapeutics
The biotechnology company is focused on overcoming historical challenges in CNS drug development, such as the lack of established target biology. Effective blood-brain barrier penetration and the viability of long-term treatment with a suitable and tolerable dosing regimen add to the challenges.
Myrobalan’s approach involves developing brain-penetrant, highly selective, orally available products.
These compounds target new mechanisms linked to demyelination and neuroinflammation, which are associated with multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease and other rare neurological ailments.
The company’s new oral neurorestorative drugs fix damage and reinstate neural function in degenerative CNS ailments with high unmet needs. The therapies being developed by Myrobalan include an antagonist to G-protein coupled receptor 17, a key target to stimulate remyelination. A colony-stimulating factor-1 receptor inhibitor is also in the pipeline. CSF1R is associated with demyelination and neuroinflammation. Myrobalan’s portfolio also includes an inhibitor of allosteric tyrosine kinase 2 to lower neuroinflammation.